NDAORALTABLETPriority Review
Approved
Feb 2018
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
3/8 — Basic
Priority Review
SYMFI LO (efavirenz; lamivudine; tenofovir disoproxil fumarate) by Viatris is fixed-dose combination of antiviral drugs efv, 3tc, and tdf with antiviral activity against hiv-1 [see ]. First approved in 2018.
Drug data last refreshed 22h ago · AI intelligence enriched Yesterday
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SYMFI LO is a fixed-dose combination tablet containing efavirenz, lamivudine, and tenofovir disoproxil fumarate for oral treatment of HIV-1 infection. It combines three antiretroviral agents—a non-nucleoside reverse transcriptase inhibitor (NNRTI), a nucleoside reverse transcriptase inhibitor (NRTI), and another NRTI—to suppress HIV replication. The product leverages a well-established three-drug regimen in a single-pill formulation to improve adherence.
$0.135BPart D
PeakProduct is in peak commercial phase with modest Part D utilization; branded team size likely stable but moderate given competition intensity (30% pressure score).
Mechanism of Action
fixed-dose combination of antiviral drugs EFV, 3TC, and TDF with antiviral activity against HIV-1 [see ].
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SYMFI LO offers stable commercial exposure in a mature HIV market with high formulary and reimbursement familiarity; however, modest Part D spending and competitive intensity suggest limited growth trajectory. Roles are primarily sales, brand management, and market access focused on defending share against newer alternatives.
Brand ManagerField Sales Representative
Worked on SYMFI LO at Viatris? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.